SOAT1 and Hodgkins lymphoma: Constitutive activity of the JAK/STAT pathway is indeed a hallmark of HRS cells, contributing to their survival and proliferation.3 Even though initial clinical trials with JAK inhibitors alone for HL patients did not show promising results, it may well be that in the combination therapy with the ICIs, the direct toxic effect of ruxolitinib on HRS cells contributes to the success of this therapy.